Published in Cancer Res on June 01, 1999
Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol (2000) 5.22
Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol (2000) 3.42
Deficiency of PTEN in Jurkat T cells causes constitutive localization of Itk to the plasma membrane and hyperresponsiveness to CD3 stimulation. Mol Cell Biol (2000) 2.06
Is PTEN loss associated with clinical outcome measures in human prostate cancer? Br J Cancer (2008) 1.66
PTEN regulation by Akt-EGR1-ARF-PTEN axis. EMBO J (2008) 1.58
Nuclear PTEN-mediated growth suppression is independent of Akt down-regulation. Mol Cell Biol (2005) 1.55
p53 inhibits alpha 6 beta 4 integrin survival signaling by promoting the caspase 3-dependent cleavage of AKT/PKB. J Cell Biol (1999) 1.46
Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice. Mol Cancer Ther (2010) 1.42
PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. PLoS One (2013) 1.39
Transforming growth factor-beta promotes invasion in tumorigenic but not in nontumorigenic human prostatic epithelial cells. Cancer Res (2006) 1.36
Deficiency of Pten accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice. BMC Mol Biol (2001) 1.36
MicroRNA-32 (miR-32) regulates phosphatase and tensin homologue (PTEN) expression and promotes growth, migration, and invasion in colorectal carcinoma cells. Mol Cancer (2013) 1.25
Apoptosis evasion: the role of survival pathways in prostate cancer progression and therapeutic resistance. J Cell Biochem (2006) 1.22
AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2. Br J Cancer (2003) 1.22
Targeting anoikis resistance in prostate cancer metastasis. Mol Aspects Med (2010) 1.19
Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation. Mol Cancer (2010) 1.16
Reduced PTEN expression in the pancreas overexpressing transforming growth factor-beta 1. Br J Cancer (2002) 1.16
PTEN overexpression suppresses proliferation and differentiation and enhances apoptosis of the mouse mammary epithelium. J Clin Invest (2002) 1.16
Inhibition of AKT survival pathway by a small molecule inhibitor in human endometrial cancer cells. Br J Cancer (2004) 1.09
Shank-interacting protein-like 1 promotes tumorigenesis via PTEN inhibition in human tumor cells. J Clin Invest (2010) 1.09
Regulation of COX-2 protein expression by Akt in endometrial cancer cells is mediated through NF-kappaB/IkappaB pathway. Mol Cancer (2004) 1.07
Calcium-dependent regulation of the cell cycle via a novel MAPK--NF-kappaB pathway in Swiss 3T3 cells. J Cell Biol (2004) 1.02
Phosphatidylinositol 3-kinase inhibitor(LY294002) induces apoptosis of human nasopharyngeal carcinoma in vitro and in vivo. J Exp Clin Cancer Res (2010) 0.98
Notch signaling in prostate cancer: a moving target. Prostate (2014) 0.98
Regulators of gene expression as biomarkers for prostate cancer. Am J Cancer Res (2012) 0.98
PTEN inhibits BMI1 function independently of its phosphatase activity. Mol Cancer (2009) 0.97
Inositol hexaphosphate suppresses growth and induces apoptosis in prostate carcinoma cells in culture and nude mouse xenograft: PI3K-Akt pathway as potential target. Cancer Res (2009) 0.95
Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer. Oncogene (2008) 0.94
Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells. Br J Cancer (2013) 0.92
Overexpression of cyclin B1 antagonizes chemotherapeutic-induced apoptosis through PTEN/Akt pathway in human esophageal squamous cell carcinoma cells. Cancer Biol Ther (2012) 0.90
Androgen-independent prostate cancer: potential role of androgen and ErbB receptor signal transduction crosstalk. Neoplasia (2003) 0.90
Critical role of a survivin/TGF-β/mTORC1 axis in IGF-I-mediated growth of prostate epithelial cells. PLoS One (2013) 0.89
Regulation of Akt expression and phosphorylation by 17beta-estradiol in the rat uterus during estrous cycle. Reprod Biol Endocrinol (2003) 0.89
The AKT1/NF-kappaB/Notch1/PTEN axis has an important role in chemoresistance of gastric cancer cells. Cell Death Dis (2013) 0.88
Role of phosphoinositide 3-kinase in the aggressive tumor growth of HT1080 human fibrosarcoma cells. Mol Cell Biol (2001) 0.87
Opposite regulation of XIAP and Smac/DIABLO in the rat endometrium in response to 17beta-estradiol at estrus. Reprod Biol Endocrinol (2003) 0.86
Prostate cancer-specific and potent antitumor effect of a DD3-controlled oncolytic virus harboring the PTEN gene. PLoS One (2012) 0.85
Alisol B acetate induces apoptosis of SGC7901 cells via mitochondrial and phosphatidylinositol 3-kinases/Akt signaling pathways. World J Gastroenterol (2009) 0.84
Effect of lithium chloride and antineoplastic drugs on survival and cell cycle of androgen-dependent prostate cancer LNCap cells. Indian J Pharmacol (2012) 0.83
Phenotypic effects of overexpression of the MMAC1 gene in prostate epithelial cells. Br J Cancer (2000) 0.82
53BP1 suppresses tumor growth and promotes susceptibility to apoptosis of ovarian cancer cells through modulation of the Akt pathway. Oncol Rep (2012) 0.82
E3 ubiquitin protein ligase, E6-associated protein (E6-AP) regulates PI3K-Akt signaling and prostate cell growth. Biochim Biophys Acta (2010) 0.81
Radiosensitization in prostate cancer: mechanisms and targets. BMC Urol (2013) 0.81
Retroviral expression of a kinase-defective IGF-I receptor suppresses growth and causes apoptosis of CHO and U87 cells in-vivo. BMC Cancer (2002) 0.81
Curcumin inhibits cellular condensation and alters microfilament organization during chondrogenic differentiation of limb bud mesenchymal cells. Exp Mol Med (2009) 0.80
The prognostic value of phosphorylated AKT expression in non-small cell lung cancer: a meta-analysis. PLoS One (2013) 0.79
Combined Treatment of Androgen-Independent Prostate Cancer Cell Line DU145 with Chemotherapeutic Agents and Lithium Chloride: Effect on Growth Arrest and/or Apoptosis. Avicenna J Med Biotechnol (2012) 0.78
Integrated network model provides new insights into castration-resistant prostate cancer. Sci Rep (2015) 0.77
Biochemical and cellular evidence demonstrating AKT-1 as a binding partner for resveratrol targeting protein NQO2. PLoS One (2014) 0.77
BAYESIAN SPARSE GRAPHICAL MODELS FOR CLASSIFICATION WITH APPLICATION TO PROTEIN EXPRESSION DATA. Ann Appl Stat (2015) 0.77
Inhibition of transfected PTEN on human colon cancer. World J Gastroenterol (2004) 0.76
Effect of PTEN Gene Mutations and Environmental Risk Factors on the Progression and Prognosis of Bladder Cancer. Iran J Public Health (2014) 0.75
Long-term gene therapy with Del1 fragment using nonviral vectors in mice with explanted tumors. Onco Targets Ther (2016) 0.75
Jungermannenone A and B induce ROS- and cell cycle-dependent apoptosis in prostate cancer cells in vitro. Acta Pharmacol Sin (2016) 0.75
YAP1 and AR interactions contribute to the switch from androgen-dependent to castration-resistant growth in prostate cancer. Nat Commun (2015) 0.75
PTEN Inhibits Cell Proliferation, Promotes Cell Apoptosis, and Induces Cell Cycle Arrest via Downregulating the PI3K/AKT/hTERT Pathway in Lung Adenocarcinoma A549 Cells. Biomed Res Int (2016) 0.75
Elucidating the mechanism of miRNA-214 in the regulation of gingival carcinoma. Exp Ther Med (2017) 0.75
Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet (1997) 15.38
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol (1999) 8.69
Comparison of self-reported and measured height and weight. Am J Epidemiol (1982) 4.92
MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res (1997) 3.38
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene (2000) 2.81
The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res (1996) 2.76
Nutritional therapy for high blood pressure. Final report of a four-year randomized controlled trial--the Hypertension Control Program. JAMA (1987) 2.55
Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med (1996) 2.51
Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol (2000) 2.22
Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry (1998) 2.03
Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell (1998) 2.00
The major mycolic acids of Mycobacterium smegmatis. Characterization of their homologous series. J Biol Chem (1979) 1.92
Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology (2000) 1.90
Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. Cancer Res (1999) 1.88
High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci U S A (2000) 1.73
Bcl-2 maintains B cell memory. Nature (1991) 1.68
Mycolic acids. A reinvestigation. J Biol Chem (1978) 1.67
Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res (1999) 1.66
Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol (2000) 1.66
Response and progression in recurrent malignant glioma. Neuro Oncol (1999) 1.57
Evidence that c-myc mediated apoptosis does not require wild-type p53 during lymphomagenesis. Oncogene (1995) 1.55
Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Res (1998) 1.52
Resting functional connectivity between the hemispheres in childhood absence epilepsy. Neurology (2011) 1.51
Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features. Leukemia (2010) 1.51
Outcome and patterns of failure following limited-volume irradiation for malignant astrocytomas. Radiother Oncol (1991) 1.47
Suppression of human glioma growth by adenovirus-mediated Rb gene transfer. Neurology (1998) 1.46
Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. Cancer Res (1995) 1.46
Isolation, karyotype, and clonal growth of heterogeneous subpopulations of human malignant gliomas. Cancer Res (1981) 1.44
Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme. Int J Radiat Oncol Biol Phys (1995) 1.41
The autocrine loop of TGF-alpha/EGFR and brain tumors. J Neurooncol (1997) 1.40
The use of significant others as proxy raters of the quality of life of patients with brain cancer. Med Care (1997) 1.37
Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia (1996) 1.36
Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol (2000) 1.35
Growth control in cultured 3T3 fibroblasts. Assays of cell proliferation and demonstration of a growth inhibitory activity. J Cell Biol (1979) 1.30
Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res (1999) 1.28
Effect of disease burden on health-related quality of life in patients with malignant gliomas. Neuro Oncol (2000) 1.27
Resistance to radiation-induced apoptosis in Bcl-2-expressing cells is reversed by depleting cellular thiols. Oncogene (1997) 1.25
Bcl-2 expression causes redistribution of glutathione to the nucleus. Proc Natl Acad Sci U S A (1998) 1.23
NF-kappaB1 (p50) homodimers contribute to transcription of the bcl-2 oncogene. J Biol Chem (2001) 1.23
Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1. Cancer Res (1996) 1.23
Differences in transferrin response and numbers of transferrin receptors in rat and human mammary carcinoma lines of different metastatic potentials. J Cell Physiol (1993) 1.23
Temporal events in skin injury and the early adaptive responses in ultraviolet-irradiated mouse skin. Am J Pathol (2000) 1.22
Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res (1996) 1.21
Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage. Am J Pathol (2001) 1.21
Two tumor suppressive loci on chromosome 10 involved in human glioblastomas. Genes Chromosomes Cancer (1995) 1.21
Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. Eur J Cancer (2000) 1.19
Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol (2007) 1.19
A reliability test of standard-based quantitative PCR: exogenous vs endogenous standards. Mol Cell Probes (2000) 1.18
Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat Med (1998) 1.18
Elevated levels of M(r) 92,000 type IV collagenase in human brain tumors. Cancer Res (1993) 1.16
Analysis of the functional role of chromosome 10 loss in human glioblastomas. Cancer Res (1993) 1.15
Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN. Oncogene (2001) 1.14
Cell surface glycoproteins of 13762NF mammary adenocarcinoma clones of differing metastatic potentials. Exp Cell Res (1983) 1.14
Cloning and expression of an adhesin antigen of Streptococcus sanguis G9B in Escherichia coli. J Gen Microbiol (1989) 1.13
Expression of human immunodeficiency virus type I tat results in down-regulation of bcl-2 and induction of apoptosis in hematopoietic cells. Oncogene (1996) 1.13
An intermediate filament-associated protein, p50, recognized by monoclonal antibodies. J Cell Biol (1983) 1.11
TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2. Oncogene (2001) 1.11
Growth control in cultured 3T3 fibroblasts II. Molecular properties of a fraction enriched in growth inhibitory activity. J Cell Biol (1982) 1.11
Apoptosis suppression by bcl-2 is correlated with the regulation of nuclear and cytosolic Ca2+. Oncogene (1996) 1.11
Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch Gen Psychiatry (1996) 1.08
Transfer of E2F-1 to human glioma cells results in transcriptional up-regulation of Bcl-2. Cancer Res (2001) 1.07
Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. J Natl Cancer Inst (1997) 1.07
Deletion mapping of chromosome 4 in head and neck squamous cell carcinoma. Oncogene (1997) 1.06
MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells. Oncogene (2000) 1.06
Human keratin-1.bcl-2 transgenic mice aberrantly express keratin 6, exhibit reduced sensitivity to keratinocyte cell death induction, and are susceptible to skin tumor formation. Oncogene (1998) 1.05
The functional basis of c-myc and bcl-2 complementation during multistep lymphomagenesis in vivo. Exp Cell Res (1995) 1.05
Heterogeneous chemosensitivities of subpopulations of human glioma cells in culture. Cancer Res (1982) 1.05
A binary adenoviral vector system for expressing high levels of the proapoptotic gene bax. Gene Ther (2000) 1.05
Adenoviral Bak overexpression mediates caspase-dependent tumor killing. Cancer Res (2000) 1.04
Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer. Am J Clin Oncol (2001) 1.03
Altered expression and distribution of heparan sulfate proteoglycans in human gliomas. Cancer Res (1989) 1.02
Clinical trial end points in malignant glioma: need for effective trial design strategy. Semin Oncol (2000) 1.01
Maintenance therapy of duodenal ulcer with famotidine. A multicenter United States study. Am J Med (1986) 1.01
Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology. J Nutr Health Aging (2012) 1.00
Establishment and characterization of a new mantle cell lymphoma cell line, Mino. Leuk Res (2002) 1.00
Apoptosis and expression of the bcl-2 proto-oncogene in the fetal and adult human kidney: evidence for the contribution of bcl-2 expression to renal carcinogenesis. Hum Pathol (1994) 1.00
Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma. J Neurooncol (1997) 0.99
Use of [18F]fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors. Ann Neurol (1993) 0.99
Evidence that p53 and bcl-2 are regulators of a common cell death pathway important for in vivo lymphomagenesis. Oncogene (1994) 0.99
Deficiency of caspase-3 in MCF7 cells blocks Bax-mediated nuclear fragmentation but not cell death. Clin Cancer Res (2001) 0.99
Vimentin and glial fibrillary acidic protein in human brain tumors. J Neurooncol (1985) 0.99